Browsing Tag
Eisai Co.
4 posts
PRISM BioLab and Talus Bioscience aim to crack the transcription factor code with dual-platform drug discovery strategy
PRISM BioLab and Talus Bio have teamed up to crack transcription factor drug discovery. Find out how their dual-platform strategy could reshape precision medicine.
Merck and Eisai announce major win as Welireg plus Lenvima delays progression in advanced renal cell carcinoma
Find out how Merck and Eisai’s Welireg + Lenvima combo redefines kidney cancer care after immunotherapy and what this major Phase 3 win means for investors.
Merck’s kidney cancer breakthrough hits one target—Will it be enough to change how doctors treat RCC?
Merck and Eisai’s new kidney cancer combination met a key Phase 3 goal. Discover what it means for patients, investors, and the oncology landscape.
FDA accepts application for LEQEMBI subcutaneous dosing: A step forward in Alzheimer’s care
Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has accepted…